Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry

IF 2 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biomarkers Pub Date : 2024-04-12 DOI:10.1080/1354750x.2024.2342016

Alexander L. Reese-Petersen, Helene W. Breisnes, Daniel Gabor, Sarah R. Rønnow, Bruna Manoel, Mayuur Bajaj, Claus S. von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A. Karsdal

引用次数: 0

Abstract

IntroductionThere is an urgent, persistent, need for better biomarkers in clinical drug development. More informative biomarkers can increase the likelihood of drug advancement or approval, and imp...

查看原文本刊更多论文

生物标志物指导下的药物开发为患者、支付方和药物开发商带来价值：生物标志物行业 25 年的经验教训

导言在临床药物开发过程中，对更好的生物标记物的需求是迫切而持久的。信息量更丰富的生物标志物可以提高药物进步或获批的可能性，并有助于提高药物的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.